Jefferies Financial Group Brokers Decrease Earnings Estimates for IDEAYA Biosciences, Inc. (NASDAQ: IDYA)

IDEAYA Biosciences, Inc. (NASDAQ: IDYA – Get Rating) – Equities researchers at Jefferies Financial Group reduced their Q4 2022 earnings per share estimates for shares of IDEAYA Biosciences in a note issued to investors on Wednesday, May 11th. Jefferies Financial Group analyst M. Raycroft now expects that the company will post earnings per share of $ 0.49 for the quarter, down from their previous forecast of $ 0.60. IDEAYA Biosciences (NASDAQ: IDYA – Get Rating) last announced its quarterly earnings data on Tuesday, May 10th. The company reported ($ 0.36) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($ 0.41) by $ 0.05. IDEAYA Biosciences had a negative net margin of 170.82% and a negative return on equity of 19.11%.

IDYA has been the subject of a number of other reports. Zacks Investment Research raised shares of IDEAYA Biosciences from a “sell” rating to a “hold” rating in a research note on Friday, March 18th. Stifel Nicolaus raised shares of IDEAYA Biosciences from a “hold” rating to a “buy” rating and dropped their price objective for the stock from $ 27.00 to $ 20.00 in a research note on Thursday, March 10th. Finally, Wedbush reissued an “outperform” rating and issued a $ 34.00 price objective on shares of IDEAYA Biosciences in a research note on Wednesday, March 16th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, IDEAYA Biosciences presently has an average rating of “Buy” and an average price target of $ 29.40.

IDYA opened at $ 10.49 on Friday. The company has a fifty day moving average of $ 11.05 and a 200 day moving average of $ 16.52. IDEAYA Biosciences has a fifty-two week low of $ 8.14 and a fifty-two week high of $ 28.00.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Janus Henderson Group PLC acquired a new stake in IDEAYA Biosciences in the third quarter valued at approximately $ 6,835,000. Rafferty Asset Management LLC purchased a new position in shares of IDEAYA Biosciences during the third quarter worth approximately $ 802,000. Dimensional Fund Advisors LP purchased a new position in shares of IDEAYA Biosciences during the third quarter worth approximately $ 2,337,000. Deutsche Bank AG grew its position in IDEAYA Biosciences by 13.1% in the 3rd quarter. Deutsche Bank AG now owns 18,844 shares of the company’s stock valued at $ 480,000 after buying an additional 2,181 shares during the last quarter. Finally, AXA SA grew its position in IDEAYA Biosciences by 16.1% in the 3rd quarter. AXA SA now owns 278,733 shares of the company’s stock valued at $ 7,105,000 after buying an additional 38,626 shares during the last quarter. 89.79% of the stock is currently owned by institutional investors.

About IDEAYA Biosciences (Get Rating)

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company’s lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I / II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations.

Read More

Earnings History and Estimates for IDEAYA Biosciences (NASDAQ: IDYA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Should you invest $ 1,000 in IDEAYA Biosciences right now?

Before you consider IDEAYA Biosciences, you’ll want to hear this.

MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on … and IDEAYA Biosciences wasn’t on the list.

While IDEAYA Biosciences currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

View The 5 Stocks Here

.

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker